Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
García-Corbacho, Javier
138  Ergebnisse:
Personensuche X
?
1

HMGB1 Expression Levels Correlate with Response to Immunoth..:

González-Cao, Maria ; Cai, Xueting ; Bracht, Jilian...
Lung Cancer: Targets and Therapy.  15 (2024)  - p. 55-67 , 2024
Link: https://doi.org/10.2147/..
 
?
2

Correction to: Determinants of activity and efficacy of ant..:

García-Corbacho, Javier ; Indacochea, Alberto ; González Navarro, Azucena E....
Cancer Immunology, Immunotherapy.  72 (2023)  6 - p. 1725-1726 , 2023
Link: https://doi.org/10.1007/..
 
?
3

Determinants of activity and efficacy of anti-PD1/PD-L1 the..:

García-Corbacho, Javier ; Indacochea, Alberto ; González Navarro, Azucena E....
Cancer Immunology, Immunotherapy.  72 (2023)  6 - p. 1709-1723 , 2023
Link: https://doi.org/10.1007/..
 
?
4

Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Co..:

Boni, Valentina ; Fidler, Mary J. ; Arkenau, Hendrik-Tobias...
Clinical Cancer Research.  28 (2022)  10 - p. 2020-2029 , 2022
Link: https://doi.org/10.1158/..
 
?
5

Characteristics, origin, and potential for cancer diagnosti..:

Hudecova, Irena ; Smith, Christopher G. ; Hänsel-Hertsch, Robert...
Genome Research.  32 (2021)  2 - p. 215-227 , 2021
Link: https://doi.org/10.1101/..
 
?
6

CX-072 (pacmilimab), a Probody®PD-L1 inhibitor, in advanced..:

Naing, Aung ; Thistlethwaite, Fiona ; De Vries, Elisabeth G.E....
Journal for ImmunoTherapy of Cancer.  9 (2021)  7 - p. e002447 , 2021
Link: https://doi.org/10.1136/..
 
?
7

Case Report: A Case Study Documenting the Activity of Atezo..:

Brasó-Maristany, Fara ; Sansó, Miriam ; Chic, Nuria...
Frontiers in Oncology.  11 (2021)  - p. , 2021
Link: https://doi.org/10.3389/..
 
?
8

CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combinat..:

Sanborn, Rachel E ; Hamid, Omid ; de Vries, Elisabeth GE...
Journal for ImmunoTherapy of Cancer.  9 (2021)  7 - p. e002446 , 2021
Link: https://doi.org/10.1136/..
 
?
9

A phase I/II study of epertinib plus trastuzumab with or wi..:

Macpherson, Iain R. ; Spiliopoulou, Pavlina ; Rafii, Saeed...
Breast Cancer Research.  22 (2019)  1 - p. , 2019
Link: https://doi.org/10.1186/..
 
?
10

A phase I pharmacokinetic and safety study of cabazitaxel i..:

Azaro, Analía ; Rodón, Jordi ; Machiels, Jean-Pascal...
Cancer Chemotherapy and Pharmacology.  78 (2016)  6 - p. 1185-1197 , 2016
Link: https://doi.org/10.1007/..
 
?
11

Determinants of activity and efficacy of anti-PD1/PD-L1 the..:

GARCIA-CORBACHO, JAVIER ; Indacochea Cusirramos, Alberto ; GONZALEZ NAVARRO, EUROPA AZUCENA...
Cancer Immunology, Immunotherapy;.  , 2023
Link: https://hdl.handle.net/1..
 
?
12

Determinants of activity and efficacy of anti-PD1/PD-L1 the..:

García-Corbacho, Javier ; Indacochea, Alberto ; González Navarro, Azucena E...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10198872/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
13

Correction to: Determinants of activity and efficacy of ant..:

García-Corbacho, Javier ; Indacochea, Alberto ; González Navarro, Azucena E...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10198920/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
14

Characteristics, origin, and potential for cancer diagnosti..:

Hudecova, Irena ; Smith, Christopher G ; Hänsel-Hertsch, Robert...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8805718/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
15

Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Co..:

Boni, Valentina ; Fidler, Mary J ; Arkenau, Hendrik-Tobias...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365353/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
1-15